Version: 1.0.0 | Published: 23 Sep 2026 | Updated: 0 days ago
Documentation
Description:
Human serum samples from Alzheimer"s disease driven mild cognitive impairment and non-diseased controls were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. Other neurodegenerative and non-neurodegenerative diseases were also used to help measure the specificity of the selected biomarkers (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74763).
In the study presented here, 50 Alzheimer"s disease driven mild cognitive impairment samples and 50 control human serum samples were probed onto human protein microarrays in order to identify differentially expressed autoantibodies. Microarray data was analyzed using several statistical significance algorithms, and autoantibodies that demonstrated significant differences in group prevelance were selected as potential biomarkers of disease. Prediction classification analysis using Invitrogen"s Prospector v5.2.1 and Random Forest tested the diagnostic efficacy of the identified biomarkers. Differentiation of mild cognitive impairment samples from other neurodegenerative and non-neurodegenerative controls (Parkinson"s disease, multiple sclerosis, and breast cancer) assessed the specificity of the selected biomarkers, while comparison with mild-moderate Alzheimer"s disease samples assessed their utility for use in disease staging.
contributor: Alzheimer"s Disease Neuroimagining Initiative
Platform: GPL13669 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL13669)
Coverage
Spatial:
US
Follow Up:
Unknown
Provenance
Temporal
Accrual Periodicity:
Static
Start Date:
01 January 2026
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
See dataset for details. Access data at:
Usage
Resource Creators:
GSE74763
Observations
Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Persons
100
Count
01 January 2026